LMR与妇科恶性肿瘤预后的研究进展

doi:10.11904/j.issn.1002-3070.2017.06.017

摘要/Abstract

摘要： 大量医学研究已证实炎症与肿瘤的发生、发展密切相关。在近年来的医学临床研究中,也逐渐证实并阐述了肿瘤相关性炎症反应在肿瘤的预后中发挥着重要作用。而且,肿瘤相关性炎症反应可通过患者的中性粒细胞、淋巴细胞和单核细胞等多种外周血象指标反映出来,同时,肿瘤患者的外周血淋巴细胞与单核细胞的比值,即淋巴细胞/单核细胞(LMR),在妇科恶性肿瘤的诊断及预后中发挥着重要作用。在国内外很多研究中,已将LMR在消化、血液等多个系统发生的恶性肿瘤预后中的重要作用给予阐述,而其在妇科生殖系统的肿瘤领域的研究进展,国内外鲜有报道。因此,本文主要就LMR对妇科常见恶性肿瘤预后的研究进展进行综述。

关键词: 淋巴细胞与单核细胞比值, 妇科肿瘤, 预后, 炎性因子

Abstract: A large number of medical studies have confirmed that inflammation with occurrence and development of tumor are closely related.In recent years,it has been confirmed and described that the tumor-related inflammatory response plays an important role in the prognosis of tumor.Furthermore,the tumor-related inflammatory response can be reflected by the patient's neutrophils,lymphocytes,monocytes and other peripheral blood indicators,such as peripheral blood lymphocytes and mononuclear cells ratio(LMR).LMR plays an important role in the diagnosis and prognosis of tumor patients.In many studies from China and other countries,LMR has been described digestive,blood and other systems of malignant tumors,which it plays an important role in the prognosis.There is little domestic and foreign report on the research progress of LMR on the gynecological reproductive system.Therefore,this article reviews the effect of LMR on the prognosis of common gynecological malignancies.

Key words: Lymphocyte to monocyte ratio, Gynecological tumors, Prognosis, Inflammatory factor

中图分类号:

R737

唐蒙蒙, 刘天伯, 王晶审校. LMR与妇科恶性肿瘤预后的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 569-572.

TANG Mengmeng, LIU Tianbo, WANG Jing. Recent advances in prognosis of LMR associated with gynecological malignancies[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 569-572.

参考文献

1 Virchow R.An address on the value of pathological experiments[J].Br Med J,1881,2(1075):198-203.
2 Diakos CI,Charles KA,McMillan DC,et al.Cancer-related inflammation and treatment effectiveness[J].Lancet Oncol,2014,15(11):493-503.
3 Shalapour S,Karin M.Immunity,inflammation,and cancer:an eternal fight between good and evil[J].J Clin Invest,2015,125(9):3347-3355.
4 Chan JC,Chan DL,Diakos CI,et al.The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer[J].Ann Surg,2016,265(3):539-546.
5 Minami T,Shimizu N,Yamamoto Y,et al.Identification of programmed death ligand 1-derived peptides capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma[J].J Immunother,2015,38(7):285-291.
6 Coulie PG,Van den Eynde BJ,van der Bruggen P,et al.Tumour antigens recognized by T lymphocytes:at the core of cancer immunotherapy[J].Nat Rev Cancer,2014,14(2):135-146.
7 Guo YH,Sun HF,Zhang YB,et al.The clinical use of the platelet/lymphocyte ratio and lymphocyte/monocyte ratio as prognostic predictors in colorectal cancer:a meta-analysis[J].Oncotarget,2017,8(12):20011-20024.
8 Ray-Coquard I,Cropet C,Van Glabbeke M,et al.Lymphopenia as a prognostic factor for overall survival in advanced carcinomas,sarcomas,and lymphomas[J].Cancer Res,2009,69(13):5383-5391.
9 Chanmee T,Ontong P,Konno K,et al.Tumor-associated macrophages as major players in the tumor microenvironment[J].Cancers(Basel),2014,6(3):1670-1690.
10 Szkandera J,Gerger A,Liegl-Atzwanger B,et al.The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas[J].Int J Cancer,2014,135(2):362-370.
11 Hu S,Zou Z,Li H,et al.The preoperative peripheral blood monocyte count is associated with liver metastasis and overall survival in colorectal cancer patients[J].PLoS One,2016,11(6):e0157486.
12 Kumagai S,Marumo S,Shoji T,et al.Prognostic impact of preoperative monocyte counts in patients with resected lung adenocarcinoma[J].Lung Cancer,2014,85(3):457-464.
13 Nishijima TF,Muss HB,Shachar SS,et al.Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors:A systematic review and meta-analysis[J].Cancer Treat Rev,2015,41(10):971-978.
14 Gu L,Li H,Chen L,et al.Prognostic role of lymphocyte to monocyte ratio for patients with cancer:evidence from a systematic review and meta-analysis[J].Oncotarget,2016,7(22):31926-31942.
15 Lin GN,Peng JW,Liu DY,et al.Increased lymphocyte to monocyte ratio is associated with better prognosis in patients with newly diagnosed metastatic nasopharyngeal carcinoma receiving chemotherapy[J].Tumour Biol,2014,35(11):10849-10854.
16 Aizawa M,Gotohda N,Takahashi S,et a1.Predictive value of baseline neutrophil/lymphocyte ratio for T4 disease in wall-penetrating gastric cancer[J].World J Surg,2011,35(12):2717-2722.
17 Kitayama J,Yasuda K,Kawai K,et a1.Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer[J].Radiat Oncol,2010,5(1):47.
18 Chen L,Zhang F,Sheng XG,et a1.Decreased pretreatment lymphocyte/monocyte ratio is associated with poor prognosis in stage Ib1-IIa cervical cancer patients who undergo radical surgery[J].Onco Targets Ther,2015,8:1355-1362.
19 Granados López AJ,López JA.Multistep model of cervical cancer:participation of miRNAs and coding genes[J].Int J Mol Sci,2014,15(9):15700-15733.
20 Fang H,Shuang D,Yi Z,et a1.Up-regulated microRNA-155 expression is associated with poor prognosis in cervical cancer patients[J].Biomed Pharmacother,2016,83:64-69.
21 Yang Y,Song KL,Chang H.Decreased expression of microRNA-126 is associated with poor prognosis in patients with cervical cancer[J].Diagn Pathol,2014,9(1):1-5.
22 Siegel RL,Miller KD,Jemal A.Cancer statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30.
23 Zhu JY,Liu CC,Wang L,et a1.Peripheral blood lymphocyte-to-monocyte ratio as a prognostic factor in advanced epithelial ovarian cancer:a multicenter retrospective study[J].J Cancer,2017,8(5):737-743.
24 Eo WK,Kwon S,Koh SB,et al.The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of endometrial cancer[J].J Cancer,2016,7(5):538-545.
25 Gao Y,Dai M,Liu H,et al.Diagnostic value of circulating miR-21:An update meta-analysis in various cancers and validation in endometrial cancer[J].Oncotarget,2016,7(42):68894-68908.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[3]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[4]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[5]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[6]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[7]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[8]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.
[9]	杨洪波, 石洁, 叶勇, 李文成, 邓兆平. COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 52-56.
[10]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[11]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[12]	肖洪伟, 陈升, 王艳良, 苏学良. 距肛缘≤8 cm的T₁期直肠癌患者经肛门局部切除术的预后及影响因素分析[J]. 实用肿瘤学杂志, 2018, 32(6): 545-549.
[13]	王一然, 黄维, 尹蕾, 刘琳, 周晓平, 牛星鉴, 杨悦, 安巍巍, 姬宏飞. 中性粒细胞与淋巴细胞比值对宫颈癌患者同步放化疗疗效及预后判断的临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 404-409.
[14]	李美艳, 陈永学, 侯俊德. Leptin、VEGF及不同麻醉方式对子宫内膜癌患者预后生存的影响[J]. 实用肿瘤学杂志, 2018, 32(5): 426-431.
[15]	韩滕综述, 唐丽萍审校. PD-L1的表达与妇科恶性肿瘤预后关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 468-470.